COGNITIVE PHENOTYPING: NEUROPSYCHIATRIC THERAPEUTICS (RMI)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The exploratory Center for Cognitive Phenomics (CCP) aims to accelerate identification and efficient measurement of cognitive phenotypes across syndromes and across species to advance interdisciplinary research on neuropsychiatric therapeutics. Cognitive abnormalities have been identified in all major neuropsychiatric disorders, offer quantitative phenotypes for genomic studies and clinical trials, and provide strong bridging relations to neural systems models. The CCP will iteratively refine cognitive phenotypes in interdisciplinary research using neurobehavioral, neuroimaging, and neuropsychopharmacological approaches to provide translational validation of physiological endophenotypes. The CCP will coordinate activities of a large group of experts at UCLA and elsewhere to: (1) generate cross-disorder and cross-species catalogs of phenotypes; (2) develop a phenotype selection algorithm to identify the most promising candidates for research; (3) design a phenomics database for empirical data representation, data mining, and hypothesis testing; and (4) support proof of- concept pilot projects. To advance these aims the CCP will initiate core services for: High Throughput Cognitive Phenotyping; Neuroimaging; and Translational Neuropsychopharmacology. The CCP will initially leverage UCLA campus-wide resources to provide bridging infrastructure and expertise in: Genomics, Pharmacogenomics and Statistical Genetics; Biostatistics and Psychometrics; Bioinformatics; Clinical Trial Design and Regulatory Affairs; and Bioethics. The CCP aims to overcome bottlenecks in the discovery of treatments for neuropsychiatric syndromes that are caused by the use of traditional behavioral "symptom" phenotypes, which are heterogeneous and overlapping, and difficult to translate to basic research. The long-term goal is establishment of a mature CCP that will provide the international research community with efficient, well validated phenotype assays; a cognitive phenomics data repository linked to genomics, proteomics, and other biological knowledge-bases; and novel strategies for interdisciplinary research on neuropsychiatric therapeutics.